BeiGene looks to carve out more space in the US mar­ket, set­ting up BTK drug for 2nd blood can­cer nod

BeiGene blazed the trail for a grow­ing wave of Chi­nese on­col­o­gy drugs break­ing through in the US with an ini­tial ap­proval for BTK in­hibitor Brukin­sa back in 2019, and now the US/Chi­nese drug­mak­er has set the stage for its lead drug’s next big act.

Brukin­sa beat out a com­bi­na­tion of chemother­a­py ben­damus­tine and Roche’s Rit­ux­an in terms of ex­tend­ing the lives or halt­ing the pro­gres­sion of dis­ease in first-line pa­tients with chron­ic lym­pho­cyt­ic leukemia (CLL) or small lym­pho­cyt­ic leukemia (SLL), ac­cord­ing to topline re­sults from the Phase III SE­QUOIA study un­veiled Fri­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER